Nilotinib companion diagnostic - Novartis

Drug Profile

Nilotinib companion diagnostic - Novartis

Latest Information Update: 21 Feb 2014

Price : $50

At a glance

  • Originator Novartis
  • Class Diagnostic agents
  • Mechanism of Action
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Chronic myeloid leukaemia

Most Recent Events

  • 19 Feb 2014 Novartis and MolecularMD agree to co-develop Nilotinib companion diagnostic test for Chronic myeloid leukaemia (diagnosis)
  • 08 Nov 2012 Launched for Chronic myeloid leukaemia (diagnosis) in World (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top